Acorda Strikes Patent Deal To Delay Par's Generic Ampyra

By Vin Gurrieri (January 21, 2016, 10:48 PM EST) -- Acorda Therapeutics Inc. said Wednesday it has ended its Delaware federal court suit accusing Par Pharmaceutical Inc. of flouting four patents covering the multiple sclerosis drug Ampyra after the companies agreed to a settlement that pushes back Par's proposed generic version until approximately 2027....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!